Articles On Imugene (ASX:IMU)

Highlights Phase I clinical trial of CHECKvacc is set to proceed to the fourth dose cohort. The trial of the oncolytic virotherapy candidate is designed to treat patients with triple negative breast cancer (TNBC). The study focuses on...

The Vulcan Energy Resources Ltd (ASX: VUL) share price is pushing higher again on Tuesday. In afternoon trade, the lithium developer’s shares are up 6% to $4.55. This means the company’s shares are now up 20% since this time last week....

It’s been a bumpy but overall positive end for the S&P/ASX 200 Index (ASX: XJO) for this Friday, this week and for the 2023 financial year. The ASX 200 has finished up in the green today, recording a gain of 0.12%. That puts the ind...

ASX value shares and growth shares both went up in FY23, but value stocks did a bit better. The S&P/ASX 200 Value Index is up 8.32% in the financial year to date. If you take dividends into account, the total return for FY23 is 13.55%...

It’s the last day of the financial year and significant changes are set to take place from tomorrow. Australia’s minimum wage will increase to just above $23 per hour. Superannuation figures will also increase from 10.5 per cent to 11 p...

The S&P/ASX 200 Index (ASX: XJO) is on course to finish the week with a small decline. At the time of writing, the benchmark index is down slightly to 7,192.5 points. Four ASX shares that are not letting that hold them back today are...

Highlights Imugene’s new and significant HER-Vaxx data has been presented at the World Congress of Gastrointestinal Cancer in Barcelona. The abstract presented was about ‘HERIZON: A Phase 2 study of HER-Vaxx (IMU-131)’. The World Con...

Imugene (IMU) presents “new and significant” HER-Vaxx data at the World Congress of Gastrointestinal Cancer in Barcelona The company reported its HER-Vaxx-induced antibodies correlated with tumour reduction in patients with advanced stom...

ASX set to open lower this morning after a slow day on Wall Street overnight. ASX 200 Futures Index was in a fickle mood all morning, hovering around zero change. Health tech Immugene has some huge news from a major conference in Barcelona...

This content is created by Smallcaps Authors. [Author : Imelda Cotton] Clinical stage immuno-oncology company Imugene (ASX: IMU) has introduced “new and significant data” relating to lead candidate HER-Vaxx to delegates at the World Congr...

There were 432,000 job vacancies in May 2023 – 9,000 less than in February. The Australian Bureau of Statistics this morning revealed the two per cent drop, marking the fourth consecutive quarterly fall in available jobs. However, whi...

Imugene (IMU) receives an extension of its PD1-Vaxx patent from the United States Patent Office until 2040 The patent titled, “HUMAN PD1 Peptide Vaccines And Uses Thereof”, includes 685 days of patent term adjustments to its original exp...

Highlights The United States Patent Office has awarded a patent to the company’s immunotherapeutic PD1-Vaxx. The vaccine is being designed for patients with non-small cell lung cancer (NSCLC). The patent will expire in 2040. Clini...

This content is created by Smallcaps Authors. [Author : Imelda Cotton] Clinical stage immuno-oncology company Imugene (ASX: IMU) has been granted a patent extension by the US Patent Office to protect its immunotherapeutic PD1-Vaxx for the...

What a day for the S&P/ASX 200 Index (ASX: XJO) we had this Wednesday. After yesterday’s more tentative recovery, investors have stepped on the gas in terms of buying pressure. By the end of today’s session, the ASX 200 had risen by a...

The ASX jumps 1.1pc on better-than-expected inflation figures. Australia’s rate of inflation pulled back to 5.6 per cent for the 12 months to May, down from 6.8 per cent the previous month. This reduces pressure on the Reserve Bank to...

The All Ordinaries Index (ASX: XAO) is up a healthy 1.09% in afternoon trade, boosted by today’s unexpectedly muted inflation print. And these three ASX All Ordinaries stocks are doing more than their share of the lifting. Here’s why...

The Nickel Industries Ltd (ASX: NIC) share price is pushing higher on Wednesday morning. At the time of writing, the ASX 200 mining share is up 1.5% to 88.2 cents. However, this doesn’t change much on a year-to-date basis. The Nickel Ind...

Wilsons equity strategist Rob Crookston is a happy man. Despite the turbulence in the general market, many of his team’s S&P/ASX 200 Index (ASX: XJO) holdings in the focus portfolio enjoyed earnings upgrades in recent times. Like a pro...

The Imugene Limited (ASX: IMU) share price has continued downward in the last 12 months, with the clinical-stage immuno-oncology company declining further in 2023. Unlike the reasonable 3.5% return of the S&P/ASX All Ordinaries Index...

Argosy Minerals Limited (ASX: AGY) shares have been having a tough time in 2023. Since the start of the year, the lithium developer’s shares have lost approximately a third of their value. As a comparison, Core Lithium Ltd (ASX: CXO) sha...

Highlights IMU has welcomed Ms Kim Drapkin, a prominent US biotech executive, as Non-Executive Director. Ms Drapkin has an experience of over 25 years in the pharmaceutical and biotechnology space. She has extensive knowledge of the U...

The S&P/ASX 200 Index (ASX: XJO) is on course to end the week with a strong gain. At the time of writing, the benchmark index is up 1% to 7,247.5 points. Four ASX shares that have failed to follow the market higher today are listed be...

There were some defining moments for scores of ASX shares over the week gone by. Here are five stocks that made it to the top of my list. ASX shares that boomed during the week Nickel Industries Ltd (ASX: NIC) closed out the week with a ba...

The S&P/ASX 200 Index (ASX: XJO) traded in the green on Friday, closing the week 0.32% higher at 7,122.5 points. That sees it 0.32% lower week-on-week. Today’s gains came on the back of a strong session on Wall Street overnight. The...

Imugene says it is ready to advance to the phase of testing for its cancer-killing virus, the VAXINA MAST, having cleared patient cohorts one, two, and three, and readies itself to kickstart cohort four. The post Imugene’s [ASX:IMU] Shares...

The market is tracking higher in midday trade, up nearly 0.5 per cent. Economists from the Commonwealth Bank of Australia (CAB) have forecast the chances of Australia going into recession this year are sitting at 50 per cent. Seven o...

It’s looking like the S&P/ASX 200 Index (ASX: XJO) is heading for a positive end to the trading week, and an especially welcome start to the long weekend. At the time of writing, the ASX 200 has smoothly risen by a healthy 0.37%, putti...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to end the week on a positive note. At the time of writing, the benchmark index is up 0.4% to 7,126.8 points. Four ASX shares that are climbing more than most today ar...

It’s a bright day on the bourse, with the All Ordinaries Index (ASX: XAO) lifting 0.37% at the time of writing. And its moves have been helped and hindered by three All Ords stocks posting some significant gains and falls. The trio are o...

Imugene’s (IMU) phase one metastatic advanced solid tumours (MAST) trial evaluating its novel cancer-killing drug, VAXINIA, progresses to its fourth cohort Meanwhile, cohort one of IMU’s combination study using Pembrolizumab is cleared...

Anteris’ study is progressing well at the one year and 30-day time points Imugene’s Phase 1 trial has progressed to the next cohort level Nyrada has a new lead drug   Regenerative medicine biotech Anteris Technologies (ASX:AVR) has just p...

This content is created by Smallcaps Authors. [Author : Colin Hay] Advanced immuno-oncology specialist Imugene (ASX: IMU) is preparing for the next phase of testing of a novel cancer-killing virus. The company is preparing to test a new c...

The S&P/ASX 200 Index (ASX: XJO) finished the week in the green, gaining 0.48% on Friday to close at 7,145.1 points. That sees it having fallen 0.14% over the course of this week. It comes as the market gears up to hear the Reserve Ban...

Biotech is making a comeback in 2023 There’s been a couple of breakthroughs on the ASX this year We take a look at the ASX biotech winners in May   There are clear signs the biotech sector is springing back to life after a disappointing 2...

ASX 200 lithium shares fell against the benchmark S&P/ASX 200 Index (ASX: XJO) today. Lithium explorers that finished in the red included: Pilbara Minerals Ltd (ASX: PLS) down 1.59% Allkem Ltd (ASX: AKE) down 3.64% Core Lithi...

The ASX 200 finished the day higher, up 0.2 per cent at 7,110.8 points, after the United States’ house of representatives passed a bill to suspend the $31.4 trillion debt ceiling until 2025. Asian markets also fared well, with the Nikkei...

A new month is here, so what better time to look at some new additions to your portfolio? If you’re on the lookout for some ASX 200 stocks to buy, then it could be worth listening to what Goldman Sachs is saying this week. Buy this ASX 2...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record a solid gain. At the time of writing, the benchmark index is up 0.35% to 7,116.3 points. Four ASX shares that have failed to follow the market higher today ar...

Paradigm Bio says drug is effective in osteoarthritic dogs HeraMED signed a deal with Fond, a US-based global SaaS platform The first patient has been dosed in Imugene’s clinical trial   Late stage biotech Paradigm Biopharmaceuticals (ASX...

Highlights IMU, an Australian immuno-oncology company, has dosed first patient in the combination cohort of IMPRINTER study Imugene’s study assesses safety, efficacy, and optimal dose of PD1-Vaxx combined with atezolizumab in NSCLC pat...

This content is created by Smallcaps Authors. [Author : Imelda Cotton] Clinical stage immuno-oncology company Imugene (ASX: IMU) will collaborate with global biopharmaceutical company Roche on an Imprinter trial to evaluate the safety and...

Imugene (ASX:IMU) has announced that the first patient has been dosed in the combination cohort of the IMPRINTER trial.

After starting the day off on the wrong foot, the S&P/ASX 200 Index (ASX: XJO) tumbled even further this afternoon to close the day 1.48% lower at 7,102.8 points. The apparent driver of its tumble was the latest Aussie inflation figur...

The market shows that biotechs are making a gradual comeback in 2023 What are some of the catalysts that will push this momentum further? ASX biotechs that announced FDA breakthroughs this year   After a challenging 2022, we are finally s...

ASX rare earths share Arafura Rare Earths Ltd (ASX: ARU) has plummeted in the last three months. The company’s share price has fallen 43% from 60 cents at market close on 24 February to the current share price of 36 cents. Arafura shares...

Stockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have slipped your notice today.  It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentage terms...

The S&P/ASX 200 Index (ASX: XJO) ended the week in the green, gaining 0.59% on Friday to close at 7,279.5 points. That leaves it 0.31% higher than it was this time last week. Leading the way was the S&P/ASX 200 Information Technolo...

For the final day of the trading week, the ASX was up more than 0.5 per cent. Ship building company, Austal (ASB), has leapt more than 25 per cent to crack the $2 dollar mark. It came off the back of news its US subsidiary won a $3 bi...

This content is created by Smallcaps Authors. [Author : Filip Karinja] Cancer immunotherapy house Imugene (ASX: IMU) has received US Food and Drug Administration (FDA) approval to start a human trial targeting advanced or metastatic solid...